We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

80 hedge funds and large institutions have $124M invested in Northwest Biotherapeutics, Inc. Common stock in 2015 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 20 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 20

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

1% more funds holding

Funds holding: 7980 (+1)

3% more call options, than puts

Call options by funds: $2.74M | Put options by funds: $2.65M

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

41% less capital invested

Capital invested by funds: $211M → $124M (-$86.5M)

Holders
80
Holders Change
+1
Holders Change %
+1.27%
% of All Funds
2.1%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
9
Increased
26
Reduced
20
Closed
8
Calls
$2.74M
Puts
$2.65M
Net Calls
+$90K
Net Calls Change
+$6.75M

NWBO Hedge Fund Activity: Q4 2015 in Review

80 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q4 2015, worth a combined $124M — down 41% from $211M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new NWBO positions and 8 closed out — a net gain of 1 holder — while 26 added to existing stakes and 20 trimmed.

The largest buyer was Woodford Investment Management, adding an estimated $26.2M. The largest seller was Credit Suisse, cutting an estimated $3.81M.

  • 80 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q4 2015, up from 79 in Q3 2015.
  • Funds reported $124M of Northwest Biotherapeutics, Inc. Common stock stock for Q4 2015, down 41% quarter-over-quarter.
  • 9 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q4 2015 and 8 closed out, a net change of +1 holder.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q4 2015 was Woodford Investment Management, an estimated $26.2M added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q4 2015 was Credit Suisse, an estimated $3.81M sold.

Based on aggregated 13F filings for Q4 2015.